“Nanomerics uses leading know-how in pharmaceutical nanotechnology to overcome the limitations of current medicines and develop products that deliver patient benefit in areas of unmet medical need.”
Nanomerics is a speciality pharmaceutical company focused on the development of pharmaceutical products with enhanced bioavailability. The company uses proprietary pharmaceutical nanotechnology and know-how developed over the last 14 years at the Universities of Strathclyde and Glasgow and at the UCL School of Pharmacy.
Nanomerics’ technology addresses bioavailability challenges for a broad range of therapeutics, including low molecular weight hydrophobic drugs, peptides, and nucleic acid based therapeutics (plasmid, siRNA, miRNA). Specific administration routes for which the technology has demonstrated clear advantages include the oral route, transport across the blood-brain-barrier, delivery to solid tumours, as well as to the eye.
Nanomerics’ technology platforms have the potential to capture value in a number of high value markets where bioavailability enhanced products can offer significant advantages and help address unmet medical needs.